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Abstract
Imputation has been widely used in genome-wide association studies (GWAS) to infer genotypes of un-genotyped variants
based on the linkage disequilibrium in external reference panels such as the HapMap and 1000 Genomes. However,
imputation has only rarely been performed based on family relationships to infer genotypes of un-genotyped individuals.
Using 8998 Framingham Heart Study (FHS) participants genotyped with Affymetrix 550K SNPs, we imputed genotypes of
same set of SNPs for additional 3121 participants, most of whom were never genotyped due to lack of DNA sample. Prior to
imputation, 122 pedigrees were too large to be handled by the imputation software Merlin. Therefore, we developed a
novel pedigree splitting algorithm that can maximize the number of genotyped relatives for imputing each un-genotyped
individual, while keeping new sub-pedigrees under a pre-specified size. In GWAS of four phenotypes available in FHS
(Alzheimer disease, circulating levels of fibrinogen, high-density lipoprotein cholesterol, and uric acid), we compared results
using genotyped individuals only with results using both genotyped and imputed individuals. We studied the impact of
applying different imputation quality filtering thresholds on the association results and did not found a universal threshold
that always resulted in a more significant p-value for previously identified loci. However most of these loci had a lower p-
value when we only included imputed genotypes with with $60% SNP- and $50% person-specific imputation certainty. In
summary, we developed a novel algorithm for splitting large pedigrees for imputation and found a plausible imputation
quality filtering threshold based on FHS. Further examination may be required to generalize this threshold to other studies.
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Introduction
There are two main types of genotypic imputation for GWAS
[1]. One type uses frequency and linkage disequilibrium (LD)
information of a reference panel such as HapMap or 1000
Genome Project to impute the genotypes of genetic variants not
included in the existing genome-wide genotyping. In the past few
years, LD-based genotype imputation has been widely applied to
GWAS that detected genetic associations for many complex
human traits. Between November 2008 and January 2012, there
were 252 publications that detected 2461 loci by using imputed
genotype data according to the GWAS catalog (http://www.
genome.gov/gwastudies).
The other type uses identity-by-descent (IBD) information in
families to impute genotypes of un-genotyped individuals using the
genotypes of their relatives. However, IBD-based genotype
imputation has not frequently been applied to GWAS with family
data. When phenotyped individuals exist who were not genotyped
– perhaps due to limited genotyping resources or lack of a DNA
sample – or poorly genotyped due to genotyping failure, poor
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e51589quality DNA, or other reasons, IBD-based genotype imputation
can be used to impute genotypes of these individuals and thereby
increase sample size that potentially leads to better statistical
power for genetic association studies.
Chen and Abecasis [2] developed an IBD-based imputation
algorithm for GWAS, based on the Lander-Green [3] and Elston-
Stewart [4] algorithms, which was implemented in their software
package Merlin (http://www.sph.umich.edu/csg/abecasis/
Merlin/) [5]. Based on 90 parents and grandparents of the Centre
d’Etude du Polymorphisme Human pedigrees who were geno-
typed with 864360 single nucleotide polymorphisms (SNPs), they
imputed the same set of SNPs for 78 offspring who were only
genotyped with sparse genotypes (6728 SNPs). They observed an
increase in power to detect association by including the imputed
samples. Scuteri A. et al. [6] is another application of IBD-based
imputation. Yet, the usefulness of IBD-based imputation has not
been evaluated in studies with complex family relationships and
with some individuals lacking any genotypes.
In the present investigation, we apply and evaluate the IBD-
based imputation in the FHS that has recruited multiple
generations of participants since 1948. The FHS sample consists
of 14428 participants from 1538 pedigrees. Only 9274 have
genotypes (Affymetrix 550K SNPs) and are part of the SNP Health
Association Resource (SHARe). Among the rest, we imputed
genotypes for those who have at least one genotyped relative using
IBD-based imputation [2]. One challenge is that some large
pedigrees exceed the computational limit of the software Merlin.
Therefore, we propose a novel algorithm that uses kinship
coefficients for splitting and trimming each large pedigree into
multiple smaller sub-pedigrees and that can optimize the number
of genotyped relatives for each un-genotyped individual in the sub-
pedigrees.
After imputation, we evaluated how different imputation-quality
filtering measures affected the results of GWAS with top SNPs for
several phenotypes including Alzheimer disease, circulating levels
of fibrinogen, high-density lipoprotein cholesterol (HDL) and uric
acid. Using plausible imputation-quality thresholds, we conduct
GWAS using the sample consisting of both genotyped and
imputed individuals and compare with the GWAS results using
genotyped individuals only.
Results
Splitting and Trimming Pedigrees
After splitting and trimming 122 pedigrees with bit size [7] (bit
size=2 * # non-founders – # founders – # un-genotyped
founder couples) over 20, we obtained 629 sub-pedigrees. In the
122 pedigrees, there were 1187 un- or poorly- genotyped
individuals with total 3068, 5405, and 3412, first, second, and
third degree well-genotyped (call rate greater than 90% and
heterozygous rate within +/25 standard deviation range from
mean) relatives, respectively. Poorly-genotyped individual is then
defined as an individual with call rate not greater than 90% and
heterozygous rate outside +/25 standard deviation range from
mean. In the 629 sub-pedigrees, 3060 (99.7%), 4431 (82.0%) and
1767 (51.8%) of the first, second, and third degree well-genotyped
relatives, respectively, are retained.
Genotype Imputation
Figure 1 presents the box plots of average imputation
certainty, the maximum of the posterior genotype probabilities
of imputed genotypes, across all SNPs for the overall 3121
imputed individuals and the imputed 1187 individuals. Overall,
the mean imputation certainty was 79.6% with standard deviation
(SD) 9.9%. Among the overall imputed sample, the Third
Generation sample had higher mean imputation certainty 86.8%
and lower SD (6.1%) than the other cohorts. When comparing the
imputation certainty from the all imputed sample to the 1187
sample in split sub-pedigrees, the sub-pedigree sample had a
higher mean certainty 83.7% and smaller SD 7.9%. Similarly, for
each generation, the mean generational imputation certainty in
the 1187 sample is higher than the 3121 sample. Figure 2
presents the mean imputation certainty plotted against minor
allele frequency (MAF). As expected, the imputation certainty
decreased as the MAF increased, because when the MAF is low,
most individuals are expected to carry the major allele homozy-
gote, which translates to a high posterior probability for the major
allele homozygote.
Figure 3 presents the scatter plot of MAF in the filtered
(person_specific imputation certainty greater than 50%) imputed
sample (Y axis) against MAF in well-genotyped sample (X axis),
where a cell represents the number of SNPs with MAFs that fall in
that cell. When the number of SNPs in a cell increases, the color of
the cell gets darker. Generally, data points are close to the 45
degree line. Among 403640 imputed SNPs, there are 23 and 368
SNPs with MAF difference (maximum 0.218) greater than 0.1 and
0.05, respectively, between well-genotyped and filtered imputed
samples.
GWAS with Genotyped Individuals
We first performed GWAS of Alzheimer disease, fibrinogen,
HDL and uric acid including the 8998 well-genotyped individuals
only. After filtering out SNPs with call rate less than 90%, HWE p-
value less than 10
26 and MAF less than 0.05, we identified 8
independent loci (either on different chromosomes or at least
6:6|107 bps away from each other) using a genome-wide
significance threshold of 1.25610
27 (Bonferroni correction of
403640 SNPs). In addition, the locus close to LIPC on
chromosome 15 for HDL – which did not reach genome-wide
significance – was included because it reached genome-wide
significance in the GWAS incorporating imputed individuals. The
results for 9 selected loci are presented in Table 1.
Evaluate the Effects of Different Imputation Certainty
Thresholds on GWAS Top Hits
Using GWAS top SNPs as positive controls, we evaluate how
the association results change with various thresholds for person-
specific certainty and SNP-specific certainty used to incorporate
genotypes of imputed individuals with that of genotyped individ-
uals. Figures S1, S2, S3, S4 present the results (-log10 p-value)
for Alzheimer disease, fibrinogen, HDL and uric acid. In each
plot, the horizontal line presents the results from GWAS using
genotyped individuals only. P-values from combined sample are
more significant than that of GWAS with genotyped individuals
only for most combinations of the person- and SNP-specific
certainty thresholds, except for rs4681 (Figure S2) and
rs10186236 (Figure S3). No combination of person- and SNP-
specific certainty threshold gives uniformly best results; also, there
is no clear relation between certainty thresholds and improvement
in p-value.
To incorporate genotypes of imputed individuals with that of
the genotyped individuals for GWAS, we choose the combination
of person-specific certainty threshold 0.5 and SNP-specific
certainty threshold 0.6 as a trade-off between quantity (sample
size) and quality. This combination generally gives slightly better
results than most of the other combinations based on our
evaluations using those top SNPs. Table 2 presents the mean
Family-Based Imputation in GWAS with Family Data
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sample and in the person-specific certainty .0.5, SNP_specific
certainty .0.6 and phenotyped sample. By using these certainty
thresholds, the median of the mean certainty improves from 0.81
(with minimum 0.66) to 0.95 (with minimum 0.93) and the average
increased certainty is about 0.16. Of note, among the 3121
imputed individuals, there are 1481, 868, 467, and 116 individuals
with person-specific certainty above 0.3, 0.5, 0.7, and 0.9,
respectively.
GWAS Using Genotyped and Imputed Individuals
We use the combination of person-specific certainty threshold
0.5 and SNP-specific certainty threshold 0.6 to combine genotype
data of imputed with genotyped individuals. With the combined
data, we redo the GWAS for Alzheimer disease, fibrinogen, HDL
and uric acid, additionally adjusted for imputation status to
account for the potential phenotypic difference between genotyped
and imputed samples. The same filters (call rate ,90%, HWE p-
value ,10
26 and MAF ,0.05) are applied as in 550K GWAS, so
we have the same SNPs for comparison. The results for the top
SNPs and the genomic control parameter l [8] from GWAS using
genotyped sample and that of using combined imputed- and
genotyped- sample are presented in Table 3. The l estimates
(1.02–1.03) show that no systematic inflation in test statistics is
observed. The increase in sample size varies from about 300 to
600, which leads to slight decrease in the standard error estimate
of the beta coefficient. Among the 9 independent loci, 7 loci
improve their statistical significance after including imputed
sample. Table 4 presents the improvement in statistical signifi-
cance level comparing the GWAS using the combined sample
versus using genotyped sample only. Except for fibrinogen, most of
the genome-wide significant SNPs have smaller p-values in GWAS
using combined sample. In addition, for both HDL and uric acid,
one additional SNP becomes genome-wide significant in GWAS
using combined sample. Figure 4 presents the –log10 p-value
scatter plots of GWAS using combined sample (Y axis) against
Figure 1. Box plots of imputation certainty in FHS imputed samples.
doi:10.1371/journal.pone.0051589.g001
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except for Fibrinogen, most of the SNPs that reach genome-wide
significance have smaller p-values from GWAS using combined
sample, as we reported.
Discussion
Using FHS sample, we have demonstrated that imputation in
general improves statistical power for GWAS, even when the
imputed individuals have not been genotyped at all. Using GWAS
top hits identified with observed genotypes as positive controls, we
explored the effects of different quality control thresholds for
incorporating genotypes of imputed individuals on the association
results. In order to perform imputation for large pedigrees that are
too complex to be handled with realistic computing power, we
developed an algorithm for splitting and trimming large pedigrees
into sub-pedigrees that can optimizes the number of closest related
genotyped relatives for each un- or poorly- genotyped individual.
Unlike imputation of un-genotyped variants using external
reference, family-based imputation is to impute un- or poorly-
genotyped individuals. As these individuals do not have any
genotypes or good quality genotypes, one cannot compute the
actual imputation quality. Therefore imputation certainty is used
as imputation quality measure.
The fact that the Third Generation cohort has better
imputation certainty over the previous two generations is a result
of more Third Generation individuals having at least one
genotyped parent, or more genotyped relatives. The proportion
of imputed Third Generation subjects having at least one parent is
91.9%, versus 0.2% and 32.3% for imputed individuals in the
Original and Offspring cohorts, respectively. The average sum of
genotyped 1
st,2
nd and 3
rd degree relatives per imputed individuals
for the Original, Offspring and Third Generation cohorts among
the 3121 imputed sample are 6.1, 5.3 and 9.2, respectively. In
addition, the average sum of genotyped 1
st,2
nd, and 3
rd degree
relatives of the Original, Offspring and Third Generation cohorts
among the 1187 individuals are 7.9, 7.1 and 9.8, respectively. This
explains why the average imputation certainty is higher in 1187
individuals than in all 3121 individuals for each generation. The
fact that the 1187 sample in split sub-pedigrees has higher mean
imputation certainty than the rest imputed sample is due to
imputed individuals in large pedigrees (thus need splitting)
generally having more genotyped relatives, among whom, the
most informative ones are retained in the split sub-pedigrees
Figure 2. Scatter plot of imputation certainty against MAF.
doi:10.1371/journal.pone.0051589.g002
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on the numbers of well-genotyped 1
st,2
nd, and 3
rd degree relatives,
the bit size and the number of members in sub-pedigree, the
numbers of genotyped 1
st and 2
nd degree relatives and the number
of members in sub-pedigree are positively associated with
imputation certainty with p-values 1:5|10{233, 3:6|10{23,
and 1:3|10{4, respectively. This indicates that most information
is contributed by the 1
st degree genotyped relatives. As the
proposed algorithm relies on the relationships within a large
pedigree, results are sensitive to any pedigree misspecification in
nature.
The imputation works well as we only have 23 and 368 SNPs
with MAF difference (maximum 0.218) greater than 0.1 and 0.05,
respectively, between well-genotyped and filtered imputed sam-
ples. The 23 SNPs have average 498 Mendelian errors, which
suggests additional useful criterion for selecting SNPs for
imputation. If the whole 3121 imputed sample is used, MAF will
be in general underestimated. This reassures the necessity of using
imputation certainty filter and the validation of our GWAS results
using incorporated genotype data.
When incorporating imputed genotype data with observed
genotype data, we consider various combinations of thresholds of
person-specific certainty and SNP-specific certainty to filter out
genotypes and individuals with lower imputation certainty.
Although we have observed improved statistical significance for
most combinations of thresholds for most of the top SNPs, there
are still a few cases (rs4681 for fibrinogen and rs10186236 for
HDL) with no improvement for any threshold combinations.
Table 2 indicates that failure to strengthen the statistical
significance is not likely due to low imputation certainty, as the
average certainties in incorporated imputed individuals for rs4681
and rs10186236 are 97.1% (top 3
rd) and 96.2% (top 4
th),
respectively, and the improvement does not seem to be associated
with high imputation certainty. The lack of improvement may be
Figure 3. Scatter plot of MAF in well-genotyped sample and filtered (person_specific imputation certainty greater than 50%)
imputed sample.
doi:10.1371/journal.pone.0051589.g003
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genotyped individuals and/or noise in the imputed genotypes.
Even though family-based imputation can increase the sample size
that leads to power increase by theory, it also introduces noise due
to the uncertainty in the imputed genotypes. There is no
imputation certainty threshold combination that consistently gives
better results than other combinations. The thresholds (person-
specific certainty .0.5 and SNP-specific certainty .0.6) we have
adopted for our sample seem working well. It may be applicable
for other studies, but examination of the sensitivity is still
warranted when applied to a different study. In addition, as
shown in Figure 2, imputation certainty decreases as MAF
increases. One can thus take MAF into consideration when
applying SNP-specific imputation certainty threshold during
quality filtering.
With both imputed sample (person-specific certainty .0.5 and
SNP-specific certainty .0.6) and genotyped sample included in
GWAS of Alzheimer disease, fibrinogen, HDL and uric acid, the
statistical significance is strengthened for 7 out of 9 independent
genome-wide significant loci, or for 98 out of 146 genome-wide
significant SNPs, while the inflation measured by genomic control
factor (l) remains similar compared with GWAS using genotyped
individuals only. Among the 7 loci, APOC1 for Alzheimer disease
has the smallest number in sample size increase (Table 2), but its
proportion of reduction in standard error of beta is the largest and
so is its increase in statistical significance (Table 3). In general one
would expect the proportion of reduction in the standard error to
be similar to the proportion of increase in the square root of
sample size [9]. The disproportional change in this case is due to
that Alzheimer disease is more common in the added imputed
sample. There are 164 cases (5.1%) in 3192 genotyped individuals
and 30 cases (10.4%) in 288 added imputed individuals. Except for
the association between DPP10 locus and HDL, all other
associations have been previously reported or confirmed by
meta-analysis [10–13]. Figures S5, S6, S7, S8, S9, S10, S11,
S12, S13 are the regional association plots by SNAP [14] for the 9
loci based on GWAS using incorporated genotype data. rs4420638
is 340 bp and 10297 bp away from APOC1 and the well-known
APOE genes, respectively. In FHS 550K data, no SNP is
genotyped in APOE and no SNP is in high linkage disequilibrium
with rs4420638. Therefore, as shown in Figures S5 for incident
Alzheimer disease, rs4420638 is the only genome-wide significant
SNP in +/2200 kb region around itself. In addition, rs4420638 is
strongly associated with APOE with p-value 3.3610
28 as
previously reported [12] in FHS. The association between
rs1800588 (LIPC) and HDL becomes genome-wide significant
Table 1. Top SNPs (p-value ,1.25E-7) from GWAS of Alzheimer disease, fibrinogen, HDL and uric acid using 550K genotype data.
Trait SNP Chr Position
{ ClosestRefGene HWE p callrate MAF* N beta se p
Alzheimer disease rs4420638
{{ 19 50114786 APOC1 0.78 0.999 0.16 3192 0.856 0.124 5.96E-12
Fibrinogen rs4681 4 155710282 FGB 0.53 0.998 0.18 7271 10.009 1.446 4.48E-12
HDL rs3764261 16 55550825 CETP 0.04 0.982 0.31 7996 3.077 0.266 5.71E-31
rs1919484 8 19913956 LPL 0.11 0.981 0.27 7999 1.948 0.276 1.76E-12
rs10186236 2 115096721 DPP10 0.21 0.999 0.19 8128 21.647 0.307 7.79E-8
rs1800588 15 56510967 LIPC 0.65 1.000 0.22 8134 1.514 0.293 2.42E-7
Uric acid rs16890979 4 9531265 SLC2A9 0.01 0.998 0.25 8229 20.352 0.022 2.64E-59
rs2231142 4 89271347 ABCG2 0.76 0.999 0.11 8234 0.246 0.031 1.46E-15
rs1165205 6 25978521 SLC17A3 0.19 0.985 0.46 8096 20.105 0.019 4.34E-8
{Position in base pairs, based on NCBI build 36.1 (hg18).
*MAF is computed in genotyped and phenotyped sample.
{{rs4420638 is a marker of the APOE haplotype.
doi:10.1371/journal.pone.0051589.t001
Table 2. Mean imputation certainty of the top SNPs in the entire 3121 imputed sample and in the person-specific certainty .0.5,
SNP-specific certainty .0.6 and phenotyped sample.
Trait SNP
mean(sd) certainty in 3121 imputed
sample N
{ mean(sd) certainty in N
Alzheimer disease rs4420638 0.838(0.162) 288 0.955(0.074)
Fibrinogen rs4681 0.824(0.161) 331 0.971(0.068)
HDL rs3764261 0.742(0.187) 512 0.928(0.128)
rs1919484 0.753(0.174) 524 0.930(0.117)
rs10186236 0.802(0.167) 431 0.962(0.072)
rs1800588 0.817(0.164) 419 0.951(0.092)
Uric acid rs16890979 0.769(0.170) 595 0.939(0.100)
rs2231142 0.884(0.142) 638 0.974(0.049)
rs1165205 0.658(0.199) 553 0.980(0.068)
{N: the number of phenotyped and imputed individuals with person-specific certainty .0.5 and SNP-specific certainty .0.6.
doi:10.1371/journal.pone.0051589.t002
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between rs13148356 in SLC2A9 and uric acid becomes genome-
wide significant after imputation indicates that rs13148356 is also
a likely truly associated variant missed by analyzing genotyped
individuals only. The associations of rs4681 (FGB) with fibrinogen
and rs10186236 (DPP10) with HDL are slightly weakened, but the
latter association has not previously been reported.
Our results demonstrate that the proposed algorithm for
splitting and trimming large pedigrees for IBD-based imputation
worked well and that including the imputed sample with
genotyped sample in GWAS generally strengthened the associa-
tion signals for loci with associations that have already been well
established. We identified a plausible imputation quality filtering
threshold based on FHS. Further examination may be required to
generalize this threshold to other studies.
Materials and Methods
Algorithm for Splitting and Trimming Large Pedigrees
The basic steps of the proposed algorithm for splitting and
trimming large pedigrees are as follows: (i) form clusters of un-
genotyped individuals with their closest (first degree) un-genotyped
relatives; (ii) construct sub-pedigrees based on clusters; (iii) check
the bit size of the sub-pedigrees; and (iv) apply trimming if the bit
size is greater than desired. Details of the algorithm and a
Figure 4. Scatter plots of –log10(p-value) from 550K GWAS and GWAS using incorporated genotype data.
doi:10.1371/journal.pone.0051589.g004
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below.
For each pedigree that needs size reduction,
1. Clustering un-genotyped individuals
1.1. Compute the number of un-genotyped first degree relatives
for each un-genotyped individual.
1.2. Form clusters by grouping un-genotyped first degree
relatives together until all un-genotyped persons are
clustered. We suggest starting from the un-genotyped
individual with fewest un-genotyped first degree relatives. It
is more efficient and can avoid large clusters that require
more trimming that may leave insufficient genotyped
individuals for imputation given a user specified bit size
limit.
2. Constructing sub-pedigrees based on un-genotyped clusters
2.1. Include genotyped blood relatives (kinship coefficient .0)
of each cluster member.
2.2. Include parents of current members (if not included).
2.3. Remove un-genotyped founder couples that only have one
child.
3. Checking bit size
3.1. If bit size is less than but not close to user specified, add
genotyped blood relatives of spouse. If bit size is greater
than user specified, do trimming. Otherwise, sub-pedigree
preparation is complete.
4. Trimming sub-pedigrees with bit size greater than user
specified
4.1. For each genotyped individual in a sub-pedigree, compute
the following scores using kinship coefficients. A genotyped
individual with more closest cluster members (score1
below) is more important for imputation and should not
be trimmed if not needed. The order of importance of the
scores is score1, score2, score3, score4, followed by score5.
a. score1: number of the closest cluster members (not
necessarily first degree)
b. score2: number of the 2
nd closest cluster members
c. score3: number of the 3
rd closest cluster members
d. score4: number of the 4
th closest cluster members
e. score5: number of the 5
th closest cluster members
4.2. Identify roots (bottom level of the current sub-pedigree;
roots should not be parents) that are not cluster members.
4.3. Rank the roots by scores.
4.4. Remove person or persons with the minimum rank
Table 3. Results of top SNPs (p-value ,1.25E-7) from GWAS of Alzheimer disease, fibrinogen, HDL and uric acid using 550K
genotype data and incorporated genotype data.
genotyped subjects only genotyped and imputed subjects
Trait SNP N MAF beta se p l N MAF beta se p l
Alzheimer
disease
rs4420638 3192 0.16 0.856 0.124 5.96E-12 1.02 3480 0.16 0.902 0.108 4.93E-17 1.03
Fibrinogen rs4681 7271 0.18 10.009 1.446 4.48E-12 1.03 7602 0.18 9.729 1.431 1.05E-11 1.02
HDL rs3764261 7996 0.31 3.077 0.266 5.71E-31 1.03 8508 0.32 3.155 0.259 3.15E-34 1.02
rs1919484 7999 0.27 1.948 0.276 1.76E-12 8523 0.27 2.020 0.270 7.59E-14
rs10186236 8128 0.19 21.647 0.307 7.79E-8 8559 0.19 21.577 0.301 1.62E-7
rs1800588 8134 0.22 1.514 0.293 2.42E-7 8553 0.22 1.548 0.288 8.09E-8
Uric acid rs16890979 8229 0.25 20.352 0.022 2.64E-59 1.03 8824 0.23 20.351 0.021 8.13E-61 1.02
rs2231142 8234 0.11 0.246 0.031 1.46E-15 8872 0.10 0.248 0.030 2.86E-16
rs1165205 8096 0.46 20.105 0.019 4.34E-8 8649 0.47 20.109 0.019 6.96E-9
doi:10.1371/journal.pone.0051589.t003
Table 4. Number of genome-wide significant SNPs (p-value ,1.25E-7) with improved statistical significance (smaller p-value) from
GWAS of Alzheimer disease, fibrinogen, HDL and uric acid using incorporated genotype data (new GWAS).
Trait # SNPs with smaller p/# SNPs with p,1.25E-7 in 550K GWAS
# SNPs with p,1.25E-7 in new GWAS but not in 550K
GWAS
Alzheimer disease 1/1 0
Fibrinogen 0/4 0
HDL 14/15 1
Uric acid 83/126 1
doi:10.1371/journal.pone.0051589.t004
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remove their founder-parents, too.
b. Compute bit size and repeat step 4.4 until bit size is
less than user specified.
4.5. If bit size is less than user specified within 2 bits, trimming
is done; otherwise, add back latest removed genotyped
persons, so that the bit size is as close to and less than user
specified.
4.6. If a sub-pedigree is a subset of another sub-pedigree,
remove it.
Example: Consider the example pedigree presented in Figure 5
by kinship2 package (http://cran.r-project.org/web/packages/
kinship2/), the original pedigree (top left panel) has 34 pedigree
members and bit size of 36. A grey cell represents an individual
not offering consent to participate in a study of interest, a black cell
represents an individual to be imputed, and an empty cell
represents a genotyped individual. The number under each cell is
the individual ID. There are 7 individuals to be imputed in this
pedigree (IDs 104, 106, 107, 108, 120, 132, 135) and they form 4
clusters in the following order, the 1
st by 107, the 2
nd by 132 and
120, the 3
rd by 135, the 4
th by 104, 106 and 108. The other 3
panels in Figure 5 present the final 3 sub-pedigrees. Sub-pedigree
1 with bit size 20 is formed by the 2
nd cluster. Sub-pedigree 2 with
bit size 20 is formed by the 3
rd cluster. Sub-pedigree 3 with bit size
20 is formed by the 4
th cluster and contains the sub-pedigree
formed by the 1
st cluster. ID 132 appears in sub-pedigrees 1 and 2,
as ID 132 belongs to the 2
nd cluster, genotypes imputed based on
sub-pedigree 1 will be used for ID 132. The pedigree splitting and
trimming scripts written in R are available on readers’ request.
Figure 5. Example for pedigree splitting and trimming.
doi:10.1371/journal.pone.0051589.g005
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genotyped individuals with as many closely related genotyped
relatives as possible. Between sub-pedigrees, there may be overlaps
of genotyped individuals or un-genotyped individuals. The
imputation is performed using one pedigree at a time; therefore,
overlapping is not an issue. But the original pedigrees should be
used in association analyses, not the split pedigrees.
The Framingham Heart Study (FHS) Sample
The FHS was initiated in 1948 with the enrollment of 5209 men
and women (referred to as the Original cohort) from Framingham,
MA, who underwent biennial examinations [15]. In 1971, 5124
children and spouses of these children of the Original cohort
(referred to as the Offspring cohort) were recruited and examined
approximately every four years [16]. In 2002, 4095 Third
Generation cohort participants were enrolled [17].
In 2007, genome-wide genotyping of SNPs was performed for
9274 individuals using an Affymetrix 550K SNPs platform; 8998
participants were well-genotyped, that is, call rate greater than
90% and heterozygous rate within +/25 standard deviation range
from mean. Among un-genotyped individuals and 276 poorly-
genotyped (not well-genotyped) individuals, 3121 (from 928
pedigrees) with at least one genotyped blood relative and with
consent for genetic studies, can be included for genotype
imputation. The 3121 individuals included 1990, 946 and 185
Original, Offspring and Third Generation cohorts, respectively.
All individuals included in this study provided written informed
consent, and study protocols were approved by the Institutional
Review Boards of Boston University. Merlin [5] was used in
genotype imputation, and we found the smallest bit size of the
pedigrees that Merlin failed to impute is 20. Therefore, we applied
the proposed algorithm to split and trim the 122 pedigrees with bit
size greater than 20 and used the split sub-pedigrees for
imputation.
Phenotype Definition and Measurement
The characteristics for each trait for the sample of genotyped
and imputed individuals are presented in Table 5. Alzheimer
disease was defined as previously described using NINCDS-
ADRDA criteria [18]. Fibrinogen was measured in the Original
cohort subjects during examination cycle 10 (1966–1968) using a
modified method of Ratnoff and Menzie [19], in the Offspring
cohort during examination cycle 5 (1991–1995) and in the Third
Generation cohort during examination cycle 1 (2002–2005) using
the Clauss method [20]. Serum urate was measured during the
first examination cycle of each cohort using an autoanalyzer with a
phosphotungstic acid reagent [21], and HDL was measured using
standard enzymatic method in the Original cohort during
examination cycles 11–13 (1970–76), in the Offspring cohort
during examination cycle 6 (1996–2000) and in the Third
Generation during examination cycle 1 (2002–2005).
Statistical Analyses, Genotype Imputation and Genotype
Incorporation
GWAS of continuous traits (fibrinogen, HDL and uric acid)
were performed using a linear mixed effects model with the
additive coding of SNP genotypes as a fixed effect and with
individual-specific random intercepts correlated according to the
kinship coefficient to account for residual familial correlations
[22]. Cox proportional hazards regression implemented in R
survival package was used to model incident Alzheimer disease
(starting at age 65 years); each pedigree was treated as a cluster
and the robust variance estimate was used [23]. All analyses were
adjusted for age, sex, generation status and imputation status if
imputed individuals were included.
Based on the genotypes of 8998 well-genotyped individuals with
Affymetrix 550K SNPs, we imputed genome-wide genotype data
for the additional 3121 individuals (sparse Illumina Infinium panel
genotyping of 5759 SNPs for 150 of them were also used in the
imputation). Imputation was performed for 403640 autosomal
SNPs with good genotyping quality, that is, call rate.0.97,
MAF.0.01 and Hardy Weinberg Equilibrium (HWE) p-val-
ue.10
26, using split sub-pedigrees and original pedigrees with bit
size not greater than 20. The imputed genotype dosage data is
used in association analysis. The maximum of the posterior
genotype probabilities from genotype imputation was used as an
indicator of the imputation certainty at each SNP for each
imputed individual, which we also called SNP-specific certainty.
For each individual, we compute the proportion of SNPs with
the maximum posterior probability greater than 0.95, which is
used to define person-specific certainty. Applying person-specific
certainty threshold of 0.9 retains individuals with the proportion
greater than 0.9. In contrast, applying SNP-specific certainty
threshold of 0.6 retains individuals with imputation certainty
greater than 0.6 for each SNP – and different individuals may be
included for different SNPs.
Table 5. Sample characteristics of Alzheimer disease, fibrinogen, HDL and uric acid data in the genotyped and imputed sample.
Alzheimer
disease
Fibrinogen
(mg/dl) HDL (mg/dl)
Uric acid
(mg/dl)
Sample size 4200 8229 9453 10491
Phenotype 284 (6.8%) 321.2 (67.9) 52.6 (16.1) 5.3 (1.5)
Age 78.2 (8.2) 48.0 (12.0) 51.2 (13.2) 38.9 (9.8)
Sex (female) 2318 (55.2%) 4414 (53.6%) 5079 (53.7%) 5443 (51.9%)
Original cohort 1899 (45.2%) 1062 (13%) 2044 (21.6%) 1984 (18.9%)
Offspring cohort 2301 (54.8%) 3131 (38%) 3339 (35.3%) 4459 (42.5%)
Third Generation cohort NA 4036 (49%) 4070 (43.1%) 4048 (38.6%)
Imputed 978 (23.3%) 942 (11.4%) 1313 (13.9%) 2248 (21.4%)
Length of follow-up (years) 13.2 (8.2) NA NA NA
For continuous variables, mean value and standard deviation (in parenthesis) are presented, while for binary variables, the number of cases and its proportion (in
parenthesis) are presented.
doi:10.1371/journal.pone.0051589.t005
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association testing, various quality filtering thresholds of imputa-
tion certainty (0, 0.3, 0.5, 0.7 and 0.9 for person-specific certainty,
and 0.95, 0.9, 0.85, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, and 0 for SNP-
specific certainty) are considered to incorporate imputed individ-
uals and their imputed genotypes with observed genotypes. Each
incorporated genotype dataset is used to test the association of 8
GWAS top SNPs for Alzheimer disease, fibrinogen, HDL and uric
acid that have been previously reported and serve as positive
control. We then selected the incorporated genotype dataset that
gave the most robust (in the sense that in most cases the results are
better than results from using genotyped sample) and improved (in
the sense that in most cases the results are better than results from
using other filtering thresholds) results at the 8 SNPs to conduct
GWAS of Alzheimer disease, fibrinogen, HDL and uric acid
adjusting for the same covariates with imputation status as an
additional covariate to account for the potential phenotypic
difference between genotyped and imputed samples.
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